Hepatic steatosis

There are 621 papers on hepatic steatosis in aging research: 40 trials and 140 observational studies in people, 314 in animals, 13 in cells, 107 reviews. The newest story, Nov 16, 2026: “A protein helps control fat breakdown in mouse livers”.

Disease

621 papers study it228 more mention it276 findings

98 new papers in 30 daysSee all 849 papers on hepatic steatosis

“For MACEs, the association with hepatic steatosis was stronger in nonadvanced CKM (stages 0-2: HR: 1.51; 95% CI: 1.48-1.55)”
Complementary Cardiohepatic Prognostic Value of Hepatic Steatosis in Cardiovascular-Kidney-Metabolic SyndromeJACC. Advances2026doi:10.1016/j.jacadv.2026.103378
  • Human trial40
  • Humans140
  • Animals314
  • Cells13
  • In silico1

Interventions

115

Caloric restriction

downin mice7downin rats3no changein humans1downin humans1+1

13 studies
  1. Caloric restriction decreases hepatic steatosis in humans (combined analysis after surgical or dietary intervention) (-19.0 ± 17.3%).

    “In a combined analysis, mean ± SD hepatic fat content significantly decreased after surgical or dietary intervention by 19.0 ± 17.3%, from 12.9 ± 11.4% fat content at baseline (range 2.7–38.9) to 10.8 ± 10.2% after intervention (2.5–32.5) (P = 0.0071) (Supplementary Fig. 1B).”

    Human trialcombined analysis after surgical or dietary intervention7–9 daysn = 20

    Caloric Restriction and Weight Loss Are Primary Factors in the Early Tissue-Specific Metabolic Changes After Bariatric Surgery

    Diabetes care

  2. Caloric restriction decreases hepatic steatosis in humans (obese subjects).

    “reductions in hepatic fat were similar”

    Human trialobese subjects7-10 days

    Caloric Restriction and Weight Loss Are Primary Factors in the Early Tissue-Specific Metabolic Changes After Bariatric Surgery

    Diabetes care

  3. Caloric restriction showed no clear effect on hepatic steatosis in humans.

    “At the end of the study, no significant changes were observed in patients’ liver steatosis grades either within or between the two groups (p > 0.05), although two patients in the CR diet group had a decreased steatosis grade and one patient in the control group had an increased steatosis grade.”

    Human trial12 weeksn = 60

    Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial

    Nutrients

  4. Caloric restriction protects against hepatic steatosis in obese rats after sleeve gastrectomy.

    “CRD intake exerted the protective effects against hepatic steatosis and fibrosis, emerging as an effective adjunct to bariatric surgery for managing obesity-related MASLD.”

    Animalsin obese rats after sleeve gastrectomyliver18 weeksmales

    Calorie restriction mitigates steatotic liver disease in obese rats after bariatric surgery

    Nutrition research (New York, N.Y.)

  5. Caloric restriction decreases hepatic steatosis in mice (versus unanticipated fasting).

    “F induces hepatic steatosis, whereas CR reduces it”

    Animalsversus unanticipated fastingliver

    Circadian clocks and periodic anticipated fasting prevent fasting-associated hepatic steatosis in calorie restriction

    Cell reports

  6. Caloric restriction increases hepatic steatosis in offspring of 50% calorically restricted obese fathers.

    “HFCR-I offspring also developed altered glucose and lipid homeostasis by exhibiting impaired glucose tolerance & insulin sensitivity, dyslipidemia and steatosis.”

    Animalsin offspring of 50% calorically restricted obese fathers

    “Preconceptional paternal caloric restriction of high-fat diet-induced obesity in Wistar rats dysregulates the metabolism of their offspring via AMPK/SIRT1 pathway.”

    Research SquarePreprint

  7. Caloric restriction decreases hepatic steatosis in high-fat diet-induced obese mice.

    “CR ameliorated hepatocyte steatosis”

    Animalsin high-fat diet-induced obese miceshort-term moderateliver75% of the food eaten by HFD groupmales

    Short-term moderate caloric restriction in a high-fat diet alleviates obesity via AMPK/SIRT1 signaling in white adipocytes and liver

    Food & nutrition research

  8. Caloric restriction decreases hepatic steatosis in rats.

    “Such alterations were ameliorated by caloric restriction in combination with a mixed training protocol and/or food-intake inhibitor administration during a weight loss intervention period of 3 weeks”

    Animalscombined with mixed training protocol and/or appetite suppressant in high-fat diet-induced obese ratsliver3-week weight loss intervention

    A combined healthy strategy for successful weight loss, weight maintenance and improvement of hepatic lipid metabolism

    The Journal of nutritional biochemistry

  9. Caloric restriction decreases hepatic steatosis in mice (high-fat diet-fed mice).

    “Chronic downhill running and caloric restriction promoted liver M2 macrophages phenotype, and inhibited M1 macrophages, to attenuate chronic inflammation and ameliorate hepatic steatosis.”

    Animalshigh-fat diet-fed miceliver8 weeks

    Liver macrophages mediate effects of downhill running and caloric restriction on nonalcoholic fatty liver disease of high fat diet-fed mice

    Life sciences

  10. Caloric restriction decreases hepatic steatosis in mice (high-fat diet-induced obesity-prone model).

    “Among them, the effects of CR on hepatic steatosis were the most prominent.”

    Animalshigh-fat diet-induced obesity-prone modelliver70%males

    Role of diets and exercise in ameliorating obesity-related hepatic steatosis: Insights at the microRNA-dependent thyroid hormone synthesis and action

    Life sciences

All 14

More on Caloric restriction

GLP-1 receptor agonists

downin humans4downin reviews2downin rodents1

7 studies
  1. GLP-1 receptor agonists decrease hepatic steatosis.

    “improve hepatic steatosis and inflammation by modulating pathways such as AMP-activated protein kinase (AMPK)”

    Review

    Targeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH

    British journal of clinical pharmacology

  2. GLP-1 receptor agonists decrease hepatic steatosis in humans.

    “Clinical trials have consistently demonstrated coordinated improvements in glycaemic control, hepatic steatosis, body composition, insulin sensitivity, cardiovascular and renal outcomes, inflammatory activity, mitochondrial metabolism and energy expenditure”

    Reviewliver

    From the Incretin System to the Entero–Pancreatico–Hepatico–Systemic Polyhormonal Metabolic Homeostasis Network

    Preprints.orgPreprint

  3. GLP-1 receptor agonists decrease hepatic steatosis in MASLD and MASH.

    “improvements observed in hepatic steatosis, inflammation, and fibrosis”

    Reviewin MASLD and MASH

    BEYOND GLYCEMIC CONTROL AND WEIGHT REDUCTION: PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS ON HUMAN PHYSIOLOGY - A NARRATIVE REVIEW

    International Journal of Innovative Technologies in Social Science

  4. GLP-1 receptor agonists decrease hepatic steatosis in humans.

    “significantly reduce hepatic steatosis”

    Review

    Beyond Glycemic Control: GLP-1RA–Based Therapies and Emerging Targets Beyond the Metabolic Axis

    Preprints.orgPreprint

  5. GLP-1 receptor agonists decrease hepatic steatosis in humans.

    “GLP-1 RAs (e.g., liraglutide and semaglutide) consistently demonstrate hepatic benefits, including reductions in hepatic steatosis, improvements in liver enzyme profiles, and attenuation of fibrosis progression.”

    Reviewliver

    Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review

    World journal of gastroenterology

  6. GLP-1 receptor agonists decrease hepatic steatosis in experimental animal models of diabetes.

    “GLP-1 receptor agonists have been associated with reduced hepatic steatosis and enhanced cardiovascular function.”

    Reviewin experimental animal models of diabetes

    Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models

    Pharmaceuticals (Basel, Switzerland)

  7. GLP-1 receptor agonists decrease hepatic steatosis in patients with NAFLD.

    “GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD”

    Reviewin patients with NAFLDliver

    Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease

    International journal of molecular sciences

More on GLP-1 receptor agonists

Metformin

downin mice5downin M. unguiculatus1

6 studies
  1. Metformin decreases hepatic steatosis in M. unguiculatus (obese diabetic Mongolian gerbils).

    “Metformin lowered 2-hour post-load glucose (2hPG) and ameliorated hepatic steatosis.”

    Animalsobese diabetic Mongolian gerbilsliver100 mg/kg/day5 weeksn = 4

    Tissue-resolved transcriptomic and proteomic profiling reveals organ-specific molecular signatures associated with inter-animal variation in glycemic response to metformin in obese diabetic Mongolian gerbils

    Frontiers in endocrinology

  2. Metformin decreases hepatic steatosis in high-fat diet-induced obese FVB/N mice.

    “metformin-treated HFD mice exhibited a lower proportion of hepatic steatosis, inflammation, and necrosis.”

    Animalsin high-fat diet-induced obese FVB/N miceoralliver250 mg/kg/day

    Metformin improves hepatic steatosis in diet induced obese FVB/N mice: Alterations of glucose metabolism and hepatic splicing machinery

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  3. Metformin decreases hepatic steatosis in diet-induced obese mice.

    “metformin also alleviated adiposity and hepatic steatosis”

    Animalsin diet-induced obese miceliver

    Metformin Alleviates Steatohepatitis in Diet-Induced Obese Mice in a SIRT1-Dependent Way

    Frontiers in pharmacology

  4. Metformin protects against hepatic steatosis in mice (aging-dependent steatosis; long-term treatment).

    “reducing phospho-STAT3-miR-21 levels in C57/BL6 mice liver, by long-term treatment with metformin, protected mice from aging-dependent hepatic vesicular steatosis”

    Animalsaging-dependent steatosis; long-term treatmentliverlong-term

    Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model

    Scientific reports

  5. Metformin decreases hepatic steatosis in mice (overall reduction).

    “metformin treatment led to an overall reduction in steatosis”

    Animalsliver1%males

    Health benefits of late-onset metformin treatment every other week in mice

    NPJ aging and mechanisms of disease

  6. Metformin decreases hepatic steatosis in mice (combined with diet reversal in HFD-induced obese mice).

    “Mice treated with metformin and diet-reversal showed a dramatically improved protection against HFD-induced hepatic steatosis”

    Animalscombined with diet reversal in HFD-induced obese miceliver

    Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study

    International journal of molecular sciences

More on Metformin

Exercise

downin mice4downin humans1downin reviews1

6 studies
  1. Exercise decreases hepatic steatosis in aged MASH mice.

    “Hepatic steatosis, inflammation, and fibrosis were markedly attenuated”

    Animalsin aged MASH miceliver12 weeksmales

    Exercise ameliorates sarcopenia and metabolic dysfunction–associated steatohepatitis through activation of skeletal muscle PGC-1α/SIRT1 signaling in mice

    Research SquarePreprint

  2. Exercise decreases hepatic steatosis in aged mice on long-term high-fat diet.

    “A 6-week exercise intervention markedly ameliorated these pathologies by restoring insulin sensitivity and suppressing TGF-β/Smad-mediated fibrotic signaling.”

    Animalsin aged mice on long-term high-fat dietliver6 weeks

    Exosome-Delivered eNAMPT From Exercise Activates SIRT1 to Counteract Age-Related Hepatic Steatosis and Fibrosis

    Aging cell

  3. Exercise decreases hepatic steatosis in humans (metabolic dysfunction-associated steatotic liver disease) (At 850 MET-min/week: mean = -0.72, 95% CI -0.97 to -0.49).

    “peaking at 850 MET-min/week (mean = -0.72, 95%CI: -0.97 to -0.49).”

    Reviewmetabolic dysfunction-associated steatotic liver diseaseliver850 MET-min/weekn = 961

    Dose‒response relationship between exercise and hepatic steatosis: A systematic review with Bayesian network meta-analysis of randomized controlled trials

    Journal of sport and health science

  4. Exercise prevents hepatic steatosis in high-fat diet-fed mice.

    “Our results suggest that exercise prevents NAFLD-associated liver injury, steatosis, and fibrosis.”

    Animalsin high-fat diet-fed miceswimmingliver8 weeksmales

    Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2

    Aging

  5. Exercise decreases hepatic steatosis (independent of changes in body mass).

    “exercise can effectively reduce hepatic steatosis independent of changes in body mass”

    Reviewindependent of changes in body massliver

    Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications

    Diabetes

  6. Exercise decreases hepatic steatosis in mice (high-fat diet-induced obesity-prone model).

    “LF, CR, Que and Ex significantly ameliorated HF-induced hepatic steatosis to varying degrees”

    Animalshigh-fat diet-induced obesity-prone modeltreadmilllivermales

    Role of diets and exercise in ameliorating obesity-related hepatic steatosis: Insights at the microRNA-dependent thyroid hormone synthesis and action

    Life sciences

More on Exercise

Tirzepatide

downin mice3downin humans2downin reviews1

6 studies
  1. Tirzepatide is linked with lower hepatic steatosis in individuals with Alström syndrome (fat fraction 20% resolved in first case; 21% to 11% in second case).

    “Hepatic steatosis, with a previous fat fraction of 20%, resolved as confirmed by magnetic resonance imaging (MRI).”

    Humansin individuals with Alström syndromeliver9 to 18 monthsmalesn = 2

    Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome

    The Journal of clinical endocrinology and metabolism

  2. Tirzepatide decreases hepatic steatosis in humans.

    “Furthermore, the dual-receptor agonist tirzepatide represents a major paradigm shift, leveraging dual-receptor synergy to provide superior weight loss, optimize adipose tissue function, and reduce hepatic steatosis.”

    Review

    GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review

    Cureus

  3. Tirzepatide decreases hepatic steatosis in HFD-fed female Brca1+/- mice.

    “Treatment with the dual GLP1/GIP receptor agonist tirzepatide ameliorated systemic metabolic dysfunction and hepatic steatosis in HFD-fed female Brca1+/- mice.”

    Animalsin HFD-fed female Brca1+/- micefemales

    Brca1 heterozygosity leads to hepatic steatosis in male and female mice despite sexually dimorphic effects on systemic metabolism

    bioRxivPreprint

  4. Tirzepatide decreases hepatic steatosis in obese-diabetic mice (fat deposition reduced by 50%-70%).

    “Tzp reduced fat deposition by 50%-70%, inflammation by 60%-70%, and fibrosis by 55%.”

    Animalsin obese-diabetic miceliver10 nmol/kg4 weeksfemales

    Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice

    Menopause (New York, N.Y.)

  5. Tirzepatide decreases hepatic steatosis in mice (high-fat diet-fed Brca1+/- mice).

    “markedly reduced hepatic steatosis”

    Animalshigh-fat diet-fed Brca1+/- miceliver

    MON-325 Tirzepatide Improves Metabolic Dysfunction in High-Fat Diet-Fed Brca1+/- Mice

    ENDO 2025 abstract

  6. Tirzepatide decreases hepatic steatosis in individuals with non-alcoholic fatty liver disease.

    “tirzepatide could be a promising drug for hepatic steatosis reduction in individuals with NAFLD”

    Reviewin individuals with non-alcoholic fatty liver disease

    Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review

    Biomedicines

More on Tirzepatide

Time-restricted feeding

downin mice3downin humans1no changein mice1no changein rats1

6 studies
  1. Time-restricted feeding decreases hepatic steatosis in humans (patients with overweight or obesity and MASLD) (-25.8% vs 0.7%, p <0.001).

    “hepatic steatosis significantly decreased in the TRE group (-25.8%) compared to the SOC group (0.7%, p <0.001)”

    Human trialpatients with overweight or obesity and MASLDliver16-weekn = 333

    Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease

    Journal of hepatology

  2. Time-restricted feeding decreases hepatic steatosis in HFD mice.

    “reduced small droplet macrosteatosis in the livers of HFD mice”

    Animalsin HFD miceliver2 wkmales

    Short-term time-restricted feeding improves metabolic rhythms and liver mitochondrial bioenergetic function in high-fat diet-fed mice

    Function (Oxford, England)

  3. Time-restricted feeding showed no clear effect on hepatic steatosis in rats fed a high-fat diet.

    “TRF also failed to reduce hepatic steatosis or improve serum lipid profiles in animals fed an HFD.”

    Animalsin rats fed a high-fat diet8-h feeding windowliver6 or 9 months

    The effects of time-restricted feeding on early phases of carcinogenesis in rat liver and colon

    Frontiers in nutrition

  4. Time-restricted feeding decreases hepatic steatosis in mice (PM2.5 exposure).

    “TRF counteracts PM2.5-induced insulin resistance and hepatic steatosis”

    AnimalsPM2.5 exposureliver8-hour feeding window during ZT16-ZT24males

    Time-restricted feeding ameliorates hepatic lipid and glucose metabolism dysregulation induced by PM2.5 exposure in mice

    Ecotoxicology and environmental safety

  5. Time-restricted feeding showed no clear effect on hepatic steatosis in mice (diet-induced obese mice with NAFLD on western diet).

    “There were no changes in hepatic lipid accumulation or other characteristics of NAFLD.”

    Animalsdiet-induced obese mice with NAFLD on western dietlivertwo weeksmales

    Two-Week Isocaloric Time-Restricted Feeding Decreases Liver Inflammation without Significant Weight Loss in Obese Mice with Non-Alcoholic Fatty Liver Disease

    International journal of molecular sciences

  6. Time-restricted feeding decreases hepatic steatosis in high fat diet-fed mice.

    “reduced severity of hepatic steatosis by having access to the HFD for only 8h during their normal nocturnal feeding period”

    Animalsin high fat diet-fed miceliver7 weeks

    Time-restricted feeding improves insulin resistance and hepatic steatosis in a mouse model of postmenopausal obesity

    Metabolism: clinical and experimental

More on Time-restricted feeding

Nicotinamide riboside

downin mice5downin rats1

6 studies
  1. Nicotinamide riboside decreases hepatic steatosis in high-fat diet-fed obese rats after portal vein embolization.

    “NR supplementation restored NAD+ levels, improved liver function, increased proliferative activity, and reduced steatosis.”

    Animalsin high-fat diet-fed obese rats after portal vein embolizationliver

    Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats

    Hepatology communications

  2. Nicotinamide riboside prevents hepatic steatosis in mice given nicotine plus Coca-Cola.

    “Nic+Coke caused increased caloric intake and induced hepatic steatosis, and the addition of NR prevented these changes.”

    Animalsin mice given nicotine plus Coca-Colaliver10 weeks

    Hepatic steatosis induced by nicotine plus Coca-Cola™ is prevented by nicotinamide riboside (NR)

    Frontiers in endocrinology

  3. Nicotinamide riboside decreases hepatic steatosis in mice.

    “NR-treated mice were protected against HFD-induced triacylglycerol accumulation in skeletal muscle and displayed lower triacylglycerol levels and steatosis degree in the liver”

    Animalslivermales

    Nicotinamide Riboside Supplementation to Suckling Male Mice Improves Lipid and Energy Metabolism in Skeletal Muscle and Liver in Adulthood

    Nutrients

  4. Nicotinamide riboside decreases hepatic steatosis in HFD-induced NAFLD mice.

    “In HFD-induced NAFLD mice model, NR displayed remarkable therapeutic effects on body weight gain, hepatic steatosis, steatohepatitis, insulin resistance, mitochondrial dysfunction, apoptosis and fibrosis”

    Animalsin HFD-induced NAFLD miceliver

    NAD⁺-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin

    Theranostics

  5. Nicotinamide riboside decreases hepatic steatosis in mice (aging-associated NAFLD-like phenotypes).

    “Notably, moderate NAFLD phenotypes, including steatosis and hepatic fibrosis could be markedly corrected by NR repletion.”

    Animalsaging-associated NAFLD-like phenotypesNR-supplemented foodliver2.5 g/kg foodthree months

    Nicotinamide riboside exerts protective effect against aging-induced NAFLD-like hepatic dysfunction in mice

    PeerJ

  6. Nicotinamide riboside decreases hepatic steatosis in mice (age-induced non-alcoholic fatty liver disease).

    “NR has benefits on age-associated lipid accumulation and hepatic steatosis”

    Animalsage-induced non-alcoholic fatty liver diseasesupplemented foodliver2.5 g/kg foodthree months

    The protective effect of nicotinamide riboside against age-induced hepatic disease in mice

    Preprint

More on Nicotinamide riboside

Resveratrol

downin rats3downin humans1downin M. auratus1

5 studies
  1. Resveratrol decreases hepatic steatosis in humans (along with lifestyle modification in NAFLD patients) (P < .05).

    “Resveratrol supplementation was associated with a significant reduction in liver enzyme alanine aminotransferase, inflammatory cytokines, nuclear factor κB activity, serum cytokeratin-18, and hepatic steatosis grade, as compared with placebo supplementation”

    Human trialalong with lifestyle modification in NAFLD patientscapsule500-mg12 weeksn = 50

    Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

    Nutrition research (New York, N.Y.)

  2. Resveratrol decreases hepatic steatosis in HFD/STZ-induced diabetic rats.

    “RSV also improved diabetic symptoms, attenuated liver steatosis and increased liver glycogen accumulation.”

    Animalsin HFD/STZ-induced diabetic ratsliver30 mg/kg/d12 weeksmales

    Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression

    Diabetes, metabolic syndrome and obesity : targets and therapy

  3. Resveratrol decreases hepatic steatosis in high-fat high-fructose diet-induced metabolic syndrome.

    “Administration of resveratrol reduced liver steatosis, oxidative stress, and inflammatory state.”

    Animalsin high-fat high-fructose diet-induced metabolic syndromeoralliver30 mg/kg·bw, daily10 weeksmales

    Effects of Resveratrol Against Induced Metabolic Syndrome in Rats: Role of Oxidative Stress, Inflammation, and Insulin Resistance

    Evidence-based complementary and alternative medicine : eCAM

  4. Resveratrol protects against hepatic steatosis in high-fat diet-fed hamsters.

    “Triglyceride (TG) in liver tissue and fatty liver level were lower in group H.”

    Animalsin high-fat diet-fed hamstersliver50 mg/kgsix-week

    Protective effect of microorganism biotransformation-produced resveratrol on the high fat diet-induced hyperlipidemia, hepatic steatosis and synaptic impairment in hamsters

    International journal of medical sciences

  5. Resveratrol prevents hepatic steatosis in rats (high-fat diet-fed rats).

    “resveratrol (200 mg/kg bw) and caloric restriction (30%) partially prevented hepatic steatosis and hepatocyte ballooning”

    Animalshigh-fat diet-fed ratsliver200 mg/kg bw18 weeksmales

    Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats

    PloS one

More on Resveratrol

Liraglutide

downin mice2downin cells1

3 studies
  1. Liraglutide decreases hepatic steatosis in mice (High-fat diet-fed wild-type mice).

    “While both compounds reduced liver steatosis and inflammation in wild-type mice, only liraglutide normalized lipid composition in APP/PS1 mice.”

    AnimalsHigh-fat diet-fed wild-type miceLiver3 monthsmales

    Metabolic, Hepatic, and Neuropathological Effects of Palm11-PrRP31 and Liraglutide in High-Fat Diet-Fed APP/PS1 Mice

    Neuropharmacology

  2. Liraglutide decreases hepatic steatosis in cells (free fatty acid-treated hepatocytes).

    “Our findings showed that free fatty acids (FFA) induced hepatocyte steatosis, which was significantly reversed by LRG.”

    Cellsfree fatty acid-treated hepatocyteshepatocyte

    GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD

    Prostaglandins & other lipid mediators

  3. Liraglutide decreases hepatic steatosis in obese mice.

    “Additionally, it ameliorated diet-induced hepatic steatosis in obese mice.”

    Animalsin obese mice

    Fabrication of liraglutide-encapsulated triple layer hyaluronic acid microneedles (TLMs) for the treatment of obesity

    Lab on a chip

More on Liraglutide

Nicotinamide mononucleotide

downin mice3

3 studies
  1. Nicotinamide mononucleotide decreases hepatic steatosis in mice (high-fat diet-induced NAFLD).

    “Compared with the HFD model group, NMN intervention significantly reduced body weight and alleviated hepatic steatosis.”

    Animalshigh-fat diet-induced NAFLDliver8 weeks

    Hepatoprotective Effect of Nicotinamide Mononucleotide on High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice

    Food science & nutrition

  2. Nicotinamide mononucleotide decreases hepatic steatosis in chronic high-fat diet-fed mice.

    “NMN improved liver steatosis and insulin resistance in chronic high-fat diet (HFD) mice.”

    Animalsin chronic high-fat diet-fed miceliver

    Alleviation of hepatic insulin resistance and steatosis with NMN via improving endoplasmic reticulum-Mitochondria miscommunication in the liver of HFD mice

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  3. Nicotinamide mononucleotide decreases hepatic steatosis in mice (high-fat diet-induced).

    “contributed to reducing hepatic steatosis”

    Animalshigh-fat diet-inducedliver

    Nicotinamide mononucleotide alters body composition and ameliorates metabolic disorders induced by a high-fat diet

    IUBMB life

More on Nicotinamide mononucleotide

Intermittent calorie restriction

downin humans1downin mice1

2 studies
  1. Intermittent calorie restriction decreases hepatic steatosis in humans (versus standard of care in patients with NAFLD) (absolute reduction -6.1% [95% CI -8.1 to -4.2] vs -3.6% with standard of care).

    “The LCHF and 5:2 diets were both superior to SoC treatment in reducing steatosis”

    Human trialversus standard of care in patients with NAFLD5:2 dietliver12 weeks

    Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial

    JHEP reports : innovation in hepatology

  2. Intermittent calorie restriction decreases hepatic steatosis in mice (versus continuous high-fat diet-fed mice).

    “Compared with continuous HFD-fed mice, the mice feeding HFD+ICR have lower body weight and hepatic steatosis”

    Animalsversus continuous high-fat diet-fed miceliver50% calorie restriction on 2 days each week16 weeks

    Diet Consisting of Balanced Yogurt, Fruit, and Vegetables Modifies the Gut Microbiota and Protects Mice against Nonalcoholic Fatty Liver Disease

    Molecular nutrition & food research

More on Intermittent calorie restriction

Semaglutide + metformin

downin humans1

1 study
  1. Semaglutide + metformin decreases hepatic steatosis in humans (single patient with partial Xq deletion).

    “showed the disappearance of the sonographic characteristics suggestive of mild-to-moderate hepatic steatosis”

    Human trialsingle patient with partial Xq deletionlivermetformin 500 mg/day; semaglutide up to 1.7 mg weekly6 monthsfemalesn = 1

    Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm

    Reports (MDPI)

More on Semaglutide + metformin

Digital lifestyle intervention

downin humans1RR 1.816

1 study
  1. Digital lifestyle intervention decreases hepatic steatosis in humans (RR 1.816, 95% CI 1.102-2.992).

    “patients receiving the intervention were significantly more likely to achieve a ≥10% reduction or normalization of controlled attenuation parameter (CAP) than those in the control group”

    Human trial6 monthsn = 89

    Therapeutic Effects of a WeChat Mini-Program on Metabolic Dysfunction-Associated Fatty Liver Disease: Randomized Controlled Trial

    Journal of medical Internet research

More on Digital lifestyle intervention

Yeast-free diet

downin humans1

1 study
  1. Yeast-free diet decreases hepatic steatosis in humans after 6 months compared with standard diet.

    “While no difference was found in terms of fatty liver at 3 months in the pairwise comparisons between the diet groups, statistical significance was observed between the standard diet and both WFFD and YFD at 6 months.”

    Human trialafter 6 months compared with standard diet6 monthsn = 243

    Assessing the impact of a wheat flour and baker's yeast restricted diet vs. calorie restriction in non-alcoholic fatty liver disease patients

    Archives of medical science : AMS

More on Yeast-free diet

Wheat flour-free diet

downin humans1

1 study
  1. Wheat flour-free diet decreases hepatic steatosis in humans after 6 months compared with standard diet.

    “While no difference was found in terms of fatty liver at 3 months in the pairwise comparisons between the diet groups, statistical significance was observed between the standard diet and both WFFD and YFD at 6 months.”

    Human trialafter 6 months compared with standard diet6 monthsn = 243

    Assessing the impact of a wheat flour and baker's yeast restricted diet vs. calorie restriction in non-alcoholic fatty liver disease patients

    Archives of medical science : AMS

More on Wheat flour-free diet

All 115

Effects

7

Cardiovascular and liver outcome discrimination

upin humans1

1 study
  1. Hepatic steatosis is linked with better cardiovascular and liver outcome discrimination in humans (Adding hepatic steatosis to CKM staging).

    “Adding hepatic steatosis to CKM staging improved discrimination for both outcomes.”

    HumansAdding hepatic steatosis to CKM stagingn = 313,970

    Fatty liver helped predict heart and liver risks

    JACC. Advances

Major adverse liver events

mediatesin humans1

1 study
  1. Hepatic steatosis is linked with major adverse liver events in humans (Mediation of the association between CKM stage and major adverse liver events) (41.1% mediated).

    “For MALEs, hepatic steatosis mediated 41.1% of the association with CKM stage.”

    HumansMediation of the association between CKM stage and major adverse liver events

    Fatty liver helped predict heart and liver risks

    JACC. Advances

Myocardial infarction

no changein humans1

1 study
  1. Hepatic steatosis was not clearly linked with myocardial infarction in humans (new-onset atrial fibrillation; propensity score-matched analysis).

    “with no significant difference in MI.”

    Humansnew-onset atrial fibrillation; propensity score-matched analysis

    Fatty liver is linked to heart risks with an irregular heartbeat

    ESC Congress 2026 abstract

More on Myocardial infarction

CAD-RADS categorization

no changein humans1

1 study
  1. Hepatic steatosis was not clearly linked with CAD-RADS categorization in humans (P = .12).

    “whereas CAD-RADS distribution was similar (P = .12).”

    Humanscoronary artery170 malessn = 300

    Opportunistic Detection of Hepatic Steatosis Using Postcontrast Liver Attenuation at Coronary CT Angiography

    Radiology. Cardiothoracic imaging

More on CAD-RADS categorization

LDL-C response to statins

no changein humans1

1 study
  1. Hepatic steatosis was not clearly linked with LDL-C response to statins in humans (over 12 months).

    “revealed no significant association between hepatic steatosis and statin response”

    Humansover 12 months12 monthsn = 286

    Hepatic Steatosis and Low-Density Lipoprotein Cholesterol Response After Statin Initiation: A Prospective Cohort Analysis

    Journal of gastroenterology and hepatology

Metabolic syndrome

mediatesin humans1

1 study
  1. Hepatic steatosis is linked with metabolic syndrome in humans (mediating DI-GM-MetS association) (accounted for approximately 65% (indirect effect: -0.0263; P < 0.01)).

    “In mediation analysis, hepatic steatosis accounted for approximately 65% of the DI‐GM-MetS association (indirect effect: -0.0263; P < 0.01)”

    Humansmediating DI-GM-MetS associationfive yearsn = 4,503

    Dietary index for gut microbiota and risk of metabolic syndrome: the mediating role of hepatic steatosis in a prospective cohort study

    Diabetology & metabolic syndrome

More on Metabolic syndrome

methionine metabolism

downin mice1

1 study
  1. Hepatic steatosis decreases methionine metabolism in mice (diet-induced, in Pparg-intact mice).

    “Diet-induced steatosis reduced hepatic Pemt expression in control (Pparg-intact) mice”

    Animalsdiet-induced, in Pparg-intact micelivermales

    PPARγ-dependent and -independent regulation of methionine metabolism by diet-induced obesity and fasting in male mice

    bioRxivPreprint

Upstream

37

Cellular senescence

upin mice2upin human cells1

3 studies
  1. Cellular senescence increases hepatic steatosis in mice.

    “Aging can lead to increased hepatic steatosis”

    Animalsliver

    Hepatic-specific vitamin D receptor downregulation alleviates aging-related metabolic dysfunction-associated steatotic liver disease

    World journal of gastroenterology

  2. Cellular senescence induces hepatic steatosis in HepG2 and IHH hepatocyte cell lines.

    “this was associated with increased lipid storage, increased expression of lipid transporters and the development of hepatic steatosis.”

    Cellsin HepG2 and IHH hepatocyte cell lines

    Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH

    Frontiers in endocrinology

  3. Cellular senescence increases hepatic steatosis in mice (hepatocyte senescence induced in vitro and in vivo).

    “Conversely, inducing hepatocyte senescence promotes fat accumulation in vitro and in vivo.”

    Animalshepatocyte senescence induced in vitro and in vivoliver

    Cellular senescence drives age-dependent hepatic steatosis

    Nature communications

More on Cellular senescence

Autophagy

is required forin rats1downin reviews1

2 studies
  1. Autophagy decreases hepatic steatosis (upregulated autophagy).

    “Upregulating autophagy alleviates hepatic steatosis”

    Reviewupregulated autophagyliver

    Modulation of Autophagy: A Novel "Rejuvenation" Strategy for the Aging Liver

    Oxidative medicine and cellular longevity

  2. Autophagy is required for hepatic steatosis in rats (protective effects of caloric restriction and resveratrol against HFD-induced steatosis).

    “the SIRT1-autophagy pathway and decreased ER stress are universally required for the protective effects of moderate caloric restriction (30%) and resveratrol”

    Animalsprotective effects of caloric restriction and resveratrol against HFD-induced steatosisliver30% caloric restriction; 200 mg/kg bw resveratrol18 weeksmales

    Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats

    PloS one

More on Autophagy

HCAR2

downin mice2

2 studies
  1. HCAR2 protects against hepatic steatosis in mice (High-fat diet-fed mice; GPR109A activation with niacin).

    “Upon activation, GPR109A apparently protected against obesity and hepatic steatosis (P < 0.05).”

    AnimalsHigh-fat diet-fed mice; GPR109A activation with niacinliver8–9 weeksmales

    Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

    The Journal of nutrition

  2. HCAR2 decreases hepatic steatosis in mice (shown by knockout).

    “12-months old Gpr109a-/- mice had significantly increased liver weight, hepatic steatosis and serum markers of liver injury”

    Animalsshown by knockoutliver12 months

    Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis

    Aging

More on HCAR2

CRTC1

mediatesin mice1downin mice1

1 study
  1. CRTC1 mediates hepatic steatosis in mice (calorie restriction).

    “As a cyclic AMP effector, CRTC1 mediates anti-steatotic effects of calorie restriction (CR).”

    Animalscalorie restrictionliver

    The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation

    Scientific reports

  2. CRTC1 protects against hepatic steatosis in mice (spontaneous).

    “CRTC1 confers broad spectrum protection against hepatic steatosis development.”

    Animalsspontaneousliver

    The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation

    Scientific reports

More on CRTC1

ROMO1

downin mice1

1 study
  1. ROMO1 protects against hepatic steatosis in mice (ROMO1 overexpression in multiple mouse models of steatotic liver disease).

    “ROMO1 overexpression protects against hepatic steatosis and liver injury”

    AnimalsROMO1 overexpression in multiple mouse models of steatotic liver diseaseliver

    A protein helps control fat breakdown in mouse livers

    Nature communications

More on ROMO1

HNF4A

downin mice1

1 study
  1. HNF4A decreases hepatic steatosis in mice (hepatocyte-specific HNF4 restoration).

    “hepatocyte-specific HNF4 restoration in aged mice significantly reduced hepatic steatosis and lipid accumulation”

    Animalshepatocyte-specific HNF4 restorationhepatocyte

    Restoring a gene regulator reduced liver fat in aged mice

    bioRxivPreprint

More on HNF4A

KRT18

downin mice1

1 study
  1. KRT18 decreases hepatic steatosis in mice (liver-specific KRT18 overexpression).

    “Liver-specific KRT18 overexpression lowered circulating cholesterol, reduced atherogenic lipoproteins, and alleviated hepatic steatosis”

    Animalsliver-specific KRT18 overexpressionliver

    Liver protein lowered cholesterol in mouse experiments

    AHA Scientific Sessions 2026 abstract

More on KRT18

APOE

upin mice1

1 study
  1. APOE increases hepatic steatosis in mice (ApoE4/4 knock-in mice).

    “Here we show that ApoE4 mice develop severe hepatic steatosis, neuroinflammation and lipid raft rigidification”

    AnimalsApoE4/4 knock-in miceliverfemales

    Dietary fat rebalanced brain membrane fats in mice

    Molecular biomedicine

More on APOE

Circulating growth hormone

upin mice1

1 study
  1. Circulating growth hormone increases hepatic steatosis in mice (elevated after hepatocyte-specific GHR ablation).

    “Elevated circulating GH following hepatocyte-specific GHR ablation mediates adipose-liver crosstalk that promotes adipose lipolysis and CD36-dependent hepatic steatosis.”

    Animalselevated after hepatocyte-specific GHR ablationliver

    Deleting liver growth hormone receptors accelerates aging phenotypes and shortens lifespan in mice

    Aging cell

More on Circulating growth hormone

FOXO3

downin mice1

1 study
  1. FOXO3 protects against hepatic steatosis in mice (on regular diet; shown by hepatocyte-specific knockout).

    “h-Foxo3-/- mice exhibited hepatic steatosis and an increase in the oxidized glutathione concentration when consuming a regular diet”

    Animalson regular diet; shown by hepatocyte-specific knockoutliver

    Hepatic FoxO3 Supports Metabolic Resilience, Attenuates Age-Associated Obesity and Metabolic Dysfunction, and Mitigates Diet-Induced Steatohepatitis

    Aging and disease

More on FOXO3

All 37

Associations

42

Major adverse cardiovascular events

upin humans3HR 1.51

3 studies
  1. Hepatic steatosis is associated with major adverse cardiovascular events in humans (Nonadvanced CKM, stages 0–2) (HR 1.51, 95% CI 1.48–1.55).

    “For MACEs, the association with hepatic steatosis was stronger in nonadvanced CKM (stages 0-2: HR: 1.51; 95% CI: 1.48-1.55)”

    HumansNonadvanced CKM, stages 0–2Median 15.7-year follow-up

    Fatty liver helped predict heart and liver risks

    JACC. Advances

  2. Hepatic steatosis is associated with major adverse cardiovascular events in humans (new-onset atrial fibrillation; propensity score-matched analysis) (1.19-fold higher incidence; 72.2 vs.59.8 per 1,000 person-years; adjusted hazard ratio increased by 9%).

    “the HS group exhibited a 1.19-fold higher incidence of MACE compared to the non-HS group”

    Humansnew-onset atrial fibrillation; propensity score-matched analysis52.4% malesn = 79,551

    Fatty liver is linked to heart risks with an irregular heartbeat

    ESC Congress 2026 abstract

  3. Hepatic steatosis is associated with major adverse cardiovascular events in humans (SHR 1.21; 95% CI 1.15-1.29).

    “FLI-defined hepatic steatosis was associated with incident diabetes (SHR 1.67; 95% CI 1.59-1.76; P < 0.001) and composite MACE (SHR 1.21; 95% CI 1.15-1.29; P < 0.001).”

    HumansWithout diabetes at baseline; hepatic steatosis defined by FLI ≥ 60; multivariable adjustmentn = 142,518

    Fatty liver score linked to diabetes and cardiovascular events

    Cardiovascular diabetology

Waist-to-height ratio

upin humans1

1 study
  1. Waist-to-height ratio is associated with hepatic steatosis in humans (elevated WHtR at high-risk threshold) (PR 10.45; 95% CI 6.74-16.22).

    “elevated WHtR was associated with markedly higher prevalence of hepatic steatosis (PR 10.45; 95% CI 6.74-16.22)”

    Humanselevated WHtR at high-risk thresholdlivern = 3,905

    Waist-to-Height Ratio Outperforms BMI in Identifying Hepatic Steatosis and Fibrosis in U.S. Adults

    ADA Scientific Sessions 2026 abstract

  2. Waist-to-height ratio predicts hepatic steatosis in humans (compared with body mass index) (WAUC 0.82-0.83 vs 0.81 for BMI).

    “WHtR and WC demonstrated greater discrimination than BMI for hepatic steatosis (WAUC 0.82-0.83 vs 0.81)”

    Humanscompared with body mass indexn = 3,905

    Waist-to-Height Ratio Outperforms BMI in Identifying Hepatic Steatosis and Fibrosis in U.S. Adults

    ADA Scientific Sessions 2026 abstract

More on Waist-to-height ratio

ROMO1 expression

downin rhesus monkeys1

1 study
  1. Hepatic steatosis is associated with ROMO1 expression in rhesus monkeys (spontaneous fatty liver).

    “spontaneous fatty liver in aged rhesus macaques is associated with reduced ROMO1 expression and concomitant loss of SIRT3 protein.”

    Animalsspontaneous fatty liverliver

    A protein helps control fat breakdown in mouse livers

    Nature communications

More on ROMO1 expression

Major adverse cardiovascular events

upin humans1

1 study
  1. Hepatic steatosis is associated with major adverse cardiovascular events in humans (Patients undergoing coronary artery calcium scoring).

    “Both HS (HR 1.25 [1.07-1.46], p=0.006) and CVI (T2: HR 1.24 [1.06-1.45]; T3: HR 1.41 [1.21-1.64]; both p<0.01) were independently associated with MACE.”

    HumansPatients undergoing coronary artery calcium scoringMedian follow-up of 3.4 years

    Interplay Between Neighborhood Environment, Hepatic Steatosis, and Coronary Artery Calcium Scores: Analysis of the Houston Methodist HeartScan Cohort

    AHA Scientific Sessions 2026 abstract

More on Major adverse cardiovascular events

Baseline infrastructure vulnerability

upin humans1

1 study
  1. Baseline infrastructure vulnerability is associated with hepatic steatosis in humans (Adjusted for age, sex, and race/ethnicity).

    “In the domain analysis, baseline infrastructure vulnerability showed the strongest association with HS (OR 1.14 [1.10-1.17])”

    HumansAdjusted for age, sex, and race/ethnicityliverPer 1-SD increasen = 32,942

    Interplay Between Neighborhood Environment, Hepatic Steatosis, and Coronary Artery Calcium Scores: Analysis of the Houston Methodist HeartScan Cohort

    AHA Scientific Sessions 2026 abstract

More on Baseline infrastructure vulnerability

Neighborhood environment

upin humans1

1 study
  1. Neighborhood environment is associated with hepatic steatosis in humans.

    “Higher CVI was independently associated with greater odds of HS (T2: OR 1.11 [1.03-1.20]; T3: OR 1.27 [1.17-1.36]; both p<0.01).”

    HumansHigh versus low Climate Vulnerability Index tertile; adjusted for age, sex, and race/ethnicityliver49.9% malesn = 32,942

    Interplay Between Neighborhood Environment, Hepatic Steatosis, and Coronary Artery Calcium Scores: Analysis of the Houston Methodist HeartScan Cohort

    AHA Scientific Sessions 2026 abstract

More on Neighborhood environment

Ischemic stroke

upin humans1

1 study
  1. Hepatic steatosis is associated with ischemic stroke in humans (new-onset atrial fibrillation; propensity score-matched analysis) (adjusted hazard ratio increased by 8%).

    “PSM-adjusted hazard ratios (HRs) for MACE, HF, and ischemic stroke increased by 9%, 12%, and 8%, respectively, in the HS group”

    Humansnew-onset atrial fibrillation; propensity score-matched analysis

    Fatty liver is linked to heart risks with an irregular heartbeat

    ESC Congress 2026 abstract

More on Ischemic stroke

Heart failure hospitalization

upin humans1

1 study
  1. Hepatic steatosis is associated with heart failure hospitalization in humans (new-onset atrial fibrillation; propensity score-matched analysis) (adjusted hazard ratio increased by 12%).

    “PSM-adjusted hazard ratios (HRs) for MACE, HF, and ischemic stroke increased by 9%, 12%, and 8%, respectively, in the HS group”

    Humansnew-onset atrial fibrillation; propensity score-matched analysis

    Fatty liver is linked to heart risks with an irregular heartbeat

    ESC Congress 2026 abstract

Log-transformed lipoprotein(a) concentrations

downin humans1

1 study
  1. Hepatic steatosis is associated with log-transformed lipoprotein(a) concentrations in humans (hepatic steatosis versus no hepatic steatosis) (9% lower (95% CI: 5% to 13%)).

    “men with HS had a 9% (95% confidence interval [CI]: 5% to 13%; p<0.001) lower log-transformed Lp(a) concentrations than those without HS”

    Humanshepatic steatosis versus no hepatic steatosisserummales

    Higher liver fat content is associated with lower lipoprotein(a) concentrations in men and postmenopausal women

    ESC Congress 2026 abstract

More on Log-transformed lipoprotein(a) concentrations

Prevalent carotid plaque

upin humans1OR 1.167

1 study
  1. Hepatic steatosis is associated with prevalent carotid plaque in humans (Multivariable-adjusted association) (OR 1.167, 95% CI 1.111–1.226).

    “Ultrasound-detected hepatic steatosis was associated with higher odds of prevalent carotid plaque after multivariable adjustment (OR 1.167, 95% CI 1.111–1.226).”

    HumansMultivariable-adjusted association

    BMI–hepatic steatosis phenotypes and prevalent carotid plaque: a cross-sectional health examination study

    Scientific reports

More on Prevalent carotid plaque

All 42

Trial sponsors

Funding

2 grants since 2020

US Department of Veterans AffairsEuropean Commission€194K

Latest

Dec 2025: 11Jan 2026: 41Feb 2026: 53Mar 2026: 40Apr 2026: 18May 2026: 13Jun 2026: 22Jul 2026: 24Aug 2026: 29Sep 2026: 27Oct 2026: 71Nov 2026: 38387 papers in 12 months
Nature Communications

A protein helps control fat breakdown in mouse livers

Experiments in mouse models of fatty liver disease showed that raising the protein’s levels protected against fat buildup and liver injury.Experiments in mouse models of fatty liver disease showed that raising the protein’s levels protected against fat buildup and liver injury.

Mouse studyMechanisms

See all 849 papers on hepatic steatosis